MYC and chronic myelogenous leukemia, BCR-ABL1 positive: demonstrated that BA–c-MYC–miR-17-92 pathway could mediate enhanced miRNA expression in CML CD34+ cells at the chronic phase, resulting in the acceleration of disease progression (13).